Biocon Sees Recovery In Biosimilars
Scope To Address Affordability In US As Mylan Partnership Bears Fruit
Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.
You may also be interested in...
Strides has paused further investments in the sterile injectables business under Stelis, citing pandemic-related uncertainty and loss of revenue from ranitidine withdrawal in the US. A prior investment commitment of $40m in Stelis will, however, be fulfilled. Meanwhile, Strides reported a strong first quarter led by non-US markets.
The global collaboration agreement pairs Biocon’s insulins with Voluntis’s Insulia, the first digital therapeutic with regulatory clearance for insulin-dependent type 2 diabetes patients. Biocon further reveals plans for a complete digital therapeutics portfolio for patients
Keeping Track: US FDA Approvals Include Novel Agents Zepzelca And Uplizna, Biosimilar Nyvepria, Follow-On Semglee
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.